Nuvation Bio Inc (NUVB NYSE) stock market data APIs
$2.2999
0.09(3.9%)
as of July 10, 2025
Try our APIs with
free plan!
Nuvation Bio Inc Financial Data Overview
Price chart is built with
Anychart
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
Prev. Close
2.2999
Open
2.3937
High
2.3914
Low
2.2556
52 wk Range
1.54-3.97
Market Cap
806 M
Shares Outstanding
339 M
Revenue
10 957 K
EPS
-0.134
Beta
1.372
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nuvation Bio Inc data using free add-ons & libraries
Get Nuvation Bio Inc Fundamental Data
Nuvation Bio Inc Fundamental data includes:
- Net Revenue: 10 957 K
- EBITDA: -205 427 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.12
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nuvation Bio Inc News
New
Nuvation Bio's SWOT analysis: IBTROZI approval boosts stock prospects
Nuvation Bio Inc. (NYSE:NUVB) has recently transitioned from a clinical-stage to a commercial-stage biotechnology company with the FDA approval of its flagship drug IBTROZI (taletrectinib) for the tre...
JMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch Plans
Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 best healthcare penny stocks to buy according to analysts. JMP Securities analyst Silvan Tuerkcan maintained a “Market Outperform” rating on Nuvation...
RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating
Nuvation Bio Inc. (NYSE:NUVB) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. RBC Capital analyst Leonid Timashev maintained a Buy rating on Nuvation Bio Inc. (NYSE:NUVB) on...
Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?
Biotech research by Gorodenkoff via Shutterstock Investing in biotech penny stocks is fraught with volatility, regulatory hurdles, and uncertain clinical results. Penny stocks are companies that trad...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
